Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 640

1.
2.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

PMID:
24074008
[PubMed - indexed for MEDLINE]
Free Article
3.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

PMID:
17049139
[PubMed - indexed for MEDLINE]
Free Article
4.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

PMID:
16948890
[PubMed - indexed for MEDLINE]
Free Article
5.

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.

Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.

Arthritis Rheum. 2008 Feb 15;59(2):234-40. doi: 10.1002/art.23333.

PMID:
18240258
[PubMed - indexed for MEDLINE]
Free Article
6.

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.

Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM.

Adv Ther. 2012 Mar;29(3):234-48. doi: 10.1007/s12325-012-0007-y. Epub 2012 Mar 9.

PMID:
22411424
[PubMed - indexed for MEDLINE]
7.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

PMID:
17651658
[PubMed - indexed for MEDLINE]
Free Article
8.

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.

Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ.

Rheumatology (Oxford). 2007 Nov;46(11):1729-35.

PMID:
17956918
[PubMed - indexed for MEDLINE]
Free Article
9.

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H.

Arthritis Res Ther. 2010;12(3):R117. doi: 10.1186/ar3054. Epub 2010 Jun 16.

PMID:
20553600
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.

Health Technol Assess. 2011 Mar;15(14):1-278. doi: 10.3310/hta15140. Review.

PMID:
21439251
[PubMed - indexed for MEDLINE]
Free Article
11.

Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.

Bonafede M, Joseph GJ, Princic N, Harrison DJ.

J Med Econ. 2013 Sep;16(9):1120-8. doi: 10.3111/13696998.2013.820192. Epub 2013 Jul 18.

PMID:
23808901
[PubMed - indexed for MEDLINE]
12.

Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.

Chen JS, Makovey J, Lassere M, Buchbinder R, March LM.

Arthritis Care Res (Hoboken). 2014 Mar;66(3):464-72. doi: 10.1002/acr.22151.

PMID:
24022870
[PubMed - indexed for MEDLINE]
13.

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N.

Health Technol Assess. 2011 Feb;15(10):i-xxi, 1-329. doi: 10.3310/hta15100. Review.

PMID:
21333232
[PubMed - indexed for MEDLINE]
Free Article
14.

Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.

Haberhauer G, Strehblow C, Fasching P.

Wien Med Wochenschr. 2010 May;160(9-10):220-4. doi: 10.1007/s10354-010-0795-0.

PMID:
20632149
[PubMed - indexed for MEDLINE]
15.

Remission in psoriatic arthritis: is it possible and how can it be predicted?

Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, Grier A, Molloy M, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ.

Arthritis Res Ther. 2010;12(3):R94. doi: 10.1186/ar3021. Epub 2010 May 18.

PMID:
20482783
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S.

Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.

PMID:
19446156
[PubMed - indexed for MEDLINE]
17.

Golimumab for the treatment of psoriatic arthritis.

Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N.

Health Technol Assess. 2011 May;15 Suppl 1:87-95. doi: 10.3310/hta15suppl1/10. Review.

PMID:
21609657
[PubMed - indexed for MEDLINE]
Free Article
18.

The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.

Seitz M, Wirthmüller U, Möller B, Villiger PM.

Rheumatology (Oxford). 2007 Jan;46(1):93-6. Epub 2006 May 23.

PMID:
16720636
[PubMed - indexed for MEDLINE]
Free Article
19.

The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.

Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, Van Oijen PC, Van Riel PC.

Ann Rheum Dis. 2008 Sep;67(9):1229-34. doi: 10.1136/ard.2007.083675. Epub 2008 Jan 3.

PMID:
18174220
[PubMed - indexed for MEDLINE]
20.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.

PMID:
22563743
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk